Medicare to continue paying for breast cancer drug
Jul 1, 2011
Avastin may no longer be approved by the Food and Drug Administration following an upcoming hearing. However, a Medicare spokesperson has said that the organization will continue to fund breast cancer patients who need the drug for treatment.
"The label change will not affect our coverage," Don McLeod, a spokesperson for the Centers for Medicare and Medicaid Services, told the news source.
The FDA is scheduled to make a final decision concerning the controversial drug produced by Roche, a Swiss pharmaceutical company. Dr. Margaret Hamburg, the FDA commissioner, will make the final call following the upcoming hearing.
One in eight American women are diagnosed with breast cancer at some time in her lifetime, according to the American Cancer Society.